Lagast Nick, Carlier Charlotte, Ceelen Wim P
Department of Surgery, Ghent University, Cancer Research Institute Ghent (CRIG), Ghent B-9000, Belgium.
Department of Surgery, Ghent University, Cancer Research Institute Ghent (CRIG), Ghent B-9000, Belgium.
Surg Oncol Clin N Am. 2018 Jul;27(3):477-494. doi: 10.1016/j.soc.2018.02.003.
The presence of a peritoneal barrier results in a pharmacokinetic advantage associated with intraperitoneal (IP) delivery of anticancer drugs. The anticancer efficacy of IP chemotherapy depends, however, on its ability to penetrate the tumor stroma. Tumor tissue transport is governed by diffusion and convection and is affected by numerous physical, biological, and pharmaceutical variables. From preclinical and clinical studies, it appears that tissue penetration after IP chemotherapy delivery is very limited. Several approaches are studied in order to improve tissue penetration of small molecular and macromolecular anticancer drugs after IP instillation.
腹膜屏障的存在使得腹腔内（IP）给药的抗癌药物具有药代动力学优势。然而，IP化疗的抗癌疗效取决于其穿透肿瘤基质的能力。肿瘤组织的转运受扩散和对流控制，并受到众多物理、生物和药学变量的影响。从临床前和临床研究来看，IP化疗给药后的组织穿透似乎非常有限。为了提高小分子和大分子抗癌药物在IP灌注后的组织穿透能力，人们研究了几种方法。
